<DOC>
	<DOCNO>NCT02437591</DOCNO>
	<brief_summary>The purpose study investigate plasma pharmacokinetics ( PK ) fidaxomicin ( FDX ) primary metabolite OP-1118 Subjects Inflammatory Bowel Disease ( IBD ) C. difficile Infection ( CDI ) . This study also compare CDI clinical response microbiological response term magnitude reduction C. difficile total viable count spore count treatment FDX achieve ; time microbial eradication ; determine time negative CDI toxin assay stool specimen treatment FDX ; assess stool concentration FDX metabolite OP-1118 throughout therapy ; ass length hospital stay , readmission resource utilization IBD patient receive FDX ; record incidence severity Adverse Events ( AEs ) document impact treatment Quality Life measure change Short Inflammatory Bowel Disease Questionnaire ( IBDQ ) score .</brief_summary>
	<brief_title>Study Evaluate Pharmacokinetics Fidaxomicin Inflammatory Bowel Disease ( IBD ) Subjects With Clostridium Difficile Infection ( CDI )</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<criteria>Confirmed diagnosis history IBD least 3 month Subject active IBD define : partial MAYO score ( ulcerative colitis subject ) 2 , least 1 point originate blood stool HarveyBradshaw Index ( HBI ) ( Crohn 's disease subject ) 5 , exclude point complication CDI confirm positive accord local standard test presence C. difficile within 48 hr prior enrollment Female subject breastfeed Screening participate study Subject agree practice effective birth control Screening participate study Subject agree participate another interventional study participate study Subject receive one day dose CDI therapy within 48 hrs prior enrolment Subject unable swallow oral study medication Presence ostomy short bowel syndrome Subject current diagnosis toxic megacolon Subject willing adhere provision treatment observation specify protocol Subject enrol study previously , take investigational drug within 28 day 5 halflives , whichever longer , prior enrollment , currently participate another clinical study may influence assessment efficacy and/or safety endpoint study , opinion Sponsor Subject previously participate CDI vaccine study Subject hypersensitivity FDX component Subject condition , Investigator 's opinion , make Subject unsuitable study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>ASP2819</keyword>
	<keyword>PAR-101</keyword>
	<keyword>OPT-80</keyword>
	<keyword>Inflammatory Bowel Disease ( IBD )</keyword>
	<keyword>Clostridium difficile Infection ( CDI )</keyword>
	<keyword>fidaxomicin</keyword>
	<keyword>Dificlir</keyword>
</DOC>